EdgeMarket › What Frazier Life Sciences Management, L.P. reported owning
What Frazier Life Sciences Management, L.P. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
3.9BPositions
38Quarter
2026-03-31Shown below
38largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. | 709.4M | 18.3% | 7.7M | 96.31 | +44.4% |
| NAMS NewAmsterdam Pharma Co N.V. | 542.4M | 14.0% | 16.9M | 27.87 | +14.6% |
| ERAS Erasca, Inc. | 399.2M | 10.3% | 24.7M | 17.63 | +1107.5% |
| BBIO BridgeBio Pharma, Inc. | 256.1M | 6.6% | 3.4M | 81.50 | +66.7% |
| ARQT Arcutis Biotherapeutics, Inc. | 232.6M | 6.0% | 9.9M | 25.08 | +58.8% |
| MBX MBX Biosciences, Inc. | 198.6M | 5.1% | 6.7M | 66.33 | +386.6% |
| PHAT Phathom Pharmaceuticals, Inc. | 138.5M | 3.6% | 12.5M | 8.87 | -16.6% |
| MAZE Maze Therapeutics, Inc. | 136.3M | 3.5% | 4.6M | 29.43 | +118.3% |
| KRYS Krystal Biotech, Inc. | 124.3M | 3.2% | 481.3K | 346.58 | +137.6% |
| TRVI Trevi Therapeutics, Inc. | 118.6M | 3.1% | 9.9M | 17.96 | +142.0% |
| PVLA PALVELLA THERAPEUTICS, INC. | 110.0M | 2.8% | 882.4K | 142.04 | +181.6% |
| unmapped CUSIP 483497103 | 99.9M | 2.6% | 5.0M | — | — |
| IRON Disc Medicine, Inc. | 86.6M | 2.2% | 1.4M | 79.81 | +35.9% |
| CYTK CYTOKINETICS INC | 76.4M | 2.0% | 1.2M | 76.84 | +105.9% |
| RVMD Revolution Medicines, Inc. | 65.7M | 1.7% | 675.7K | 209.46 | +479.3% |
| DYN Dyne Therapeutics, Inc. | 57.2M | 1.5% | 3.2M | 26.10 | +118.0% |
| SVRA Savara Inc | 53.1M | 1.4% | 9.7M | 5.59 | +80.9% |
| TARS Tarsus Pharmaceuticals, Inc. | 51.1M | 1.3% | 728.6K | 72.70 | +31.2% |
| VOR Vor Biopharma Inc. | 45.4M | 1.2% | 2.5M | 23.36 | -46.9% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 42.5M | 1.1% | 1.3M | 33.09 | -10.1% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 38.2M | 1.0% | 4.0M | 9.55 | +14.0% |
| ZLAB Zai Lab Ltd | 35.8M | 0.9% | 1.9M | 26.01 | -22.4% |
| AURA Aura Biosciences, Inc. | 34.1M | 0.9% | 5.1M | 7.80 | +22.4% |
| ACAD ACADIA PHARMACEUTICALS INC | 32.0M | 0.8% | 1.4M | 29.50 | +18.3% |
| ASND Ascendis Pharma A/S | 30.5M | 0.8% | 133.3K | 253.29 | +31.4% |
| LXEO Lexeo Therapeutics, Inc. | 25.4M | 0.7% | 4.4M | 4.88 | +1.7% |
| ALKS Alkermes plc. | 24.8M | 0.6% | 700.6K | 48.33 | +66.8% |
| ACRS Aclaris Therapeutics, Inc. | 18.5M | 0.5% | 4.9M | 6.41 | +254.1% |
| GLUE Monte Rosa Therapeutics, Inc. | 16.4M | 0.4% | 1.0M | 14.30 | +222.8% |
| IMCR Immunocore Holdings plc | 14.6M | 0.4% | 484.8K | 36.88 | +13.5% |
| MNKD MANNKIND CORP | 14.5M | 0.4% | 5.9M | 4.15 | +4.5% |
| VALN Valneva SE | 14.3M | 0.4% | 2.3M | 6.96 | -39.5% |
| EOLS Evolus, Inc. | 10.8M | 0.3% | 2.6M | 8.39 | +16.0% |
| unmapped CUSIP N62509117 | 10.0M | 0.3% | 500.3K | — | — |
| ALLO Allogene Therapeutics, Inc. | 9.3M | 0.2% | 3.8M | 2.09 | +97.2% |
| AUTL Autolus Therapeutics plc | 6.1M | 0.2% | 4.4M | 2.41 | +39.3% |
| IBIO iBio, Inc. | 3.7M | 0.1% | 2.0M | 1.43 | +88.2% |
| XLO Xilio Therapeutics, Inc. | 3.6M | 0.1% | 422.5K | 9.23 | -0.6% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →